- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Careers
- About
- For Pain Patients and Professionals
Papers: 12 Mar 2022 - 18 Mar 2022
Pharmacology/Drug Development
2022
Front Neurol
13
Assessing the impact of migraine preventive treatments on acute medication consumption is important in clinical evaluation. The number of acute medication intakes per each monthly migraine day (MMD) could provide insights on migraine burden and represent a new proxy of treatment effectiveness in clinical trials and real-life studies. We evaluated the effect of monoclonal antibodies acting on calcitonin gene-related peptide (CGRP) pathway on the consumption of migraine acute medication in real-life.